Immunosuppressive therapy for acute porphyria: Safety and efficacy in a patient with bone marrow failure

Pharmacotherapy

Volumn 26, Issue 11, 2006, Pages 1662-1666

  Field, Joshua J ^a   Giannone, Leonard ^b   Bessler, Monica ^a   Blinder, Morey A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Central Illinois Hematology/Oncology   (United States)

Author keywords

Bone marrow failure; Cyclosporine; Immunosuppression; Porphyria

Indexed keywords

AMINOLEVULINIC ACID; AZATHIOPRINE; CIPROFLOXACIN; CYCLOSPORIN; GLUCOSE; HEMIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OPIATE DERIVATIVE; PORPHOBILINOGEN; PORPHOBILINOGEN DEAMINASE; PORPHOBILINOGEN SYNTHASE; TSUKUBAENOLIDE; UROPORPHYRIN;

ACUTE INTERMITTENT PORPHYRIA; ADULT; ARTICLE; BONE MARROW DEPRESSION; CASE REPORT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; RARE DISEASE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

BONE MARROW; CYCLOSPORINE; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPHILS; PORPHYRIA, ACUTE INTERMITTENT;

EID: 33750706252     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.11.1662     Document Type: Article

References (17)

1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: x-linked sideroblastic anemia and the porphyrias. In: Scriver CS, Beaudet AI, Sly WS, Valle D, eds. The molecular and metabolic bases of inherited disease, 8th ed. New York: McGraw-Hill, 2001:2991-3062.
2. Jeans JB, Savik K, Gross CR, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 1996;65(4):269-73.
3. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005;142:439-50.
4. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36(2 suppl):25S-32.
5. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for the treatment of severe aplastic anemia. Blood 1992;79:2540-6.
6. Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anemia, congenital and acquired red cell aplasia. Br J Haematol 1989;72:278-84.
7. Nunez DJ, Williams PF, Herrick AL, Evans DB, McColl KE. Renal transplantation for the chronic renal failure in acute porphyria. Nephrol Dial Transplant 1987;2:271-4.
8. Barone GW, Gurley BJ, Anderson KE, Ketel BL, Abul-Ezz SR. The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. J Clin Pharmacol 2001;41:113-15.
9. Warholm C, Wilczek H. Renal transplantation in a case of acute intermittent porphyria. J Clin Pharmacol 1992;43:1158-60.
10. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European blood and marrow transplant severe aplastic anaemia working party. Blood 1999;93(7):2191-5.
11. Mehta J, Singhal S, Menta BC. Low dose cyclosporin for severe aplastic anemia [letter]. Am J Hematol 1992;40:73.
12. Moore MR, Hift RJ. Drugs in acute porphyrias-toxicogenetic disease. Cell Mol Biol 1997;43(1):89-94.
13. Thunell S, Henrichson A, Floderus Y, et al. Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem 1992;30:599-606.
14. Cochon AC, Aldonatti C, San Martin de Viale LC, Wainstok de Calmanovici R. Evaluation of the porphyrinogenic risk of antineoplastics. J Appl Toxicol 1997;17(3):171-7.
15. Turton-Weeks S, Barone GW, Gurley BJ, et al. Pretransplant evaluation of a patient with acute intermittent porphyria. Prog Transplant 2001;11(3):214-16.
16. Allard SA, Scott JT. Systemic lupus erythematosus and acute intermittent porphyria. Br J Rheumatol 1989;28(3):254-6.
17. McCoIl KE, Thompson GG, Moore MR. Studies in laboratory animals to assess the safety of anti-inflammatory agents in acute porphyria. Ann Rheum Dis 1987;46:540-2.